Phathom Pharmaceuticals Stock (NASDAQ:PHAT)
Previous Close
$4.11
52W Range
$3.81 - $19.71
50D Avg
$5.20
200D Avg
$10.32
Market Cap
$288.99M
Avg Vol (3M)
$1.21M
Beta
0.35
Div Yield
-
PHAT Company Profile
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
PHAT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| HEPA | Hepion Pharmaceuticals, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |
| KNSA | Kiniksa Pharmaceuticals, Ltd. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| CNSP | CNS Pharmaceuticals, Inc. |
| IMMX | Immix Biopharma, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| GPCR | Structure Therapeutics Inc. |
| BPMC | Blueprint Medicines Corporation |
| CGEM | Cullinan Oncology, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |